SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-129317
Filing Date
2019-04-30
Accepted
2019-04-30 16:10:34
Documents
10
Period of Report
2019-06-13
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A d680527ddef14a.htm DEF 14A 431319
2 GRAPHIC g680527dsp001.jpg GRAPHIC 139730
3 GRAPHIC g680527dsp002.jpg GRAPHIC 156045
4 GRAPHIC g680527g09j86.jpg GRAPHIC 21232
5 GRAPHIC g680527g30y95.jpg GRAPHIC 20437
6 GRAPHIC g680527g46v29.jpg GRAPHIC 36020
7 GRAPHIC g680527g81b73.jpg GRAPHIC 20851
8 GRAPHIC g680527g85w06.jpg GRAPHIC 28501
9 GRAPHIC g680527g92r65.jpg GRAPHIC 20197
10 GRAPHIC g680527g94t16.jpg GRAPHIC 19184
  Complete submission text file 0001193125-19-129317.txt   1070069
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37465 | Film No.: 19781786
SIC: 2834 Pharmaceutical Preparations